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CYTOKINE REMOVAL
Is cytokine removal by continuous hemofiltration feasible?
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Medical Clinic II, University of Technology Aachen, Aachen, Germany
Is cytokine removal by continuous hemofiltration feasible? Pa- bodies, soluble TNF-a receptors, and IL-1 receptor an-
tients who are critically ill with acute renal failure and sepsis tagonists in double-blind, placebo controlled trials [1–8].
have extremely high mortality rates. While it seems reasonable Although a small (2 to 3%) increase in the 28-day sur-that eliminating the inflammatory mediators (such as cytokines,
vival rate has been reported with anticytokine therapy,chemokines, tumor necrosis factor-a, etc.) by continuous renal
replacement therapy (CRRT) would be effective, studies show the effect is not statistically significant. In fact, increased
that only insubstantial numbers of these mediators are removed mortality has been reported by Fisher et al with the TNF
in comparison with endogenous clearance. Mass removal seems receptor Fc fusion protein [9].only to be effective when highly permeable membranes (sieving
Another method for treating these disease entities hascoefficient of approximately 1.0) are used, there is a filtrate
volume greater than 2 liters/hour, and when the half-life of the been to eliminate cytokines and chemokines instead of
substance to be eliminated is greater than 60 minutes. Removal blocking them. A considerable number of experimental
of cytokines by membrane adsorption is another possibility. and clinical investigators have reported employing hemo-However, because the membrane surfaces are saturated after
filtration, hemodiafiltration, plasmapheresis, and adsorp-a few hours, frequent filter changes are necessary for them to
tion to eliminate cytokines and chemokines in an attemptgenerate effective adsorption of these mediators. Despite filter
changes, only a brief and transient drop in the TNF plasma to reduce the high mortality of SIRS [10]. One may
level has been observed. Controlled clinical trials are needed assume that eliminating cytokines from the plasma can
to determine whether or not CRRT actually has a beneficial
only influence its endocrine, but not the autocrine oreffect on the systemic inflammatory response syndrome (SIRS).
paracrine mode of action.
A great number of supporting and hampering factors
RESULTS OF INFLAMMATORY MEDIATOR
are involved in the complex network that leads to sepsis.
REMOVAL BY HEMOFILTRATIONThese include cytokines, chemokines, adhesion mole-
Until now, there have been many hints, but no proof,cules, E-selectin, prostaglandins, and various phagocytic
that extracorporeal elimination of septic mediators in-cells of the immune system, the systemic inflammatory
fluences the course of the disease. No studies have beenresponse syndrome (SIRS) and the counter-regulatory
able to prove that the elimination of cytokines improvesanti-inflammatory response syndrome (CARS).
The inflammatory cytokines tumor necrosis factor-a the survival rate. Most of these studies have been carried
(TNF-a) and interleukin-1 (IL-1) cause the same spec- out on patients with acute renal failure. In a meta-ana-
trum of clinical symptoms as do staphylococcal exotoxin lytic study comparing intermittently hemodialyzed to
or gram-negative endotoxins. IL-6, IL-8, and platelet- continuously hemofiltrated patients, the last group ex-
activating factor are further important elements that stim- hibited an approximately 10% better survival rate. How-
ulate inflammation. Extensive experimental and clinical ever, proof that this improvement was a result of media-
investigations are now being focused on the concept of tor elimination does not exist (abstract; Simpson et al,
blocking the biological properties of IL-1 and TNF. Block- Nephrol Dial Transplant 8:946, 1993) [11–17]. Other
ing IL-1 or TNF-a has been highly successful in patients studies have shown that partial respiratory, circulatory,
with rheumatoid arthritis, inflammatory bowel disease, or and metabolic failure can be beneficially influenced by
graft-versus-host reaction. However, despite positive ex- continuous hemofiltration. Again, the possibility that this
perience with animal models, anticytokine therapy for sep- benefit is attributable to the elimination of cytokines has
sis has been disappointing. Over 13,000 patients with septic
been discussed, but not proven [18–21].
shock have entered trials with TNF-a–neutralizing anti-
The few controlled studies on patients without renal
insufficiency, in which the influence of hemofiltration has
Key words: sepsis, SIRS, acute renal failure, cytokines, mass transfer. been investigated, have not clearly shown that mediator
elimination positively effects the course of the disease 1999 by the International Society of Nephrology
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Table 2. Efficacy of blood purificationTable 1. Extracorporeal mass removal
(mass removal during endogenous half-life)
Extracorporeal mass removal (EM) 5
mtot 5 (mi 2 mo) · t21 Filtered and adsorbed mass
Endogenous half-life
(ng)mi 5 Ci · P · t21
mo 5 Co · (p – F) · t21
Endogenous clearance (half-life) (EC) 5mh 5 mtot · half-life21 Distribution volume · Serum concentration
2
(ng)mf 5 Cf · F · half-life21
ma 5 mtot 2 mf




mtot 5 total mass removal · time21
mi 5 incoming mass · time21
mo 5 outgoing mass · time21
mh 5 mass removal · half-life21
mf 5 mass removal by filtration · half-life21
ma 5 mass removal by adsorption · half-life21 sepsis or SIRS-related factors can influence the course
B 5 blood flow ml/60 min of the disease. It is also possible that removal of isolated
P 5 plasma flow ml/60 min
mediators after a prolonged course of the disease is noF 5 filtrate volume ml/60 min
Qi 5 hematocrit inflow longer beneficial.
Ci 5 serum concentration inflow According to Fong et al, “Hence, the entire milieu of
Co 5 serum concentration outflow hormonal and cytokine mediators must be considered inCf 5 filtrate concentration
the assessment of postinjury biologic response” [40].
CALCULATING THE MASS REMOVAL
[22–25]. Even studies in hemofiltrated patients with im- OF CYTOKINES
proving circulatory conditions or in patients receiving
To judge the quality of an elimination process, it is
less catecholamine support could not show that mediator
necessary to determine not only a concentration differ-
elimination positively influenced the course of the dis-
ence but the total amount eliminated (mass removal).
ease [26, 27].
The appropriate measurements are shown in Table 1.In animal models, the survival length and rate after
Because cytokines occur in different fluids, internal stan-exposure to exotoxins and endotoxins can be improved
dards should be contained in those fluids under investiga-by the early initiation of hemofiltration [28–31], and infu-
tion. It should be kept in mind that values attained withsion of the filtrate can induce septic symptoms in healthy
an enzyme-linked immunosorbent assay (ELISA) mayanimals. However, it has not been proven that these symp-
not be the same as those achieved with a bioassay. Thistoms are caused by mediators, as it is possible that filtered
is particularly true for TNF-a, which is inactive in theexotoxins may induce the septic symptoms [32]. Hemo-
monomeric form but active in the trimeric form.filtration has shown no beneficial effect in animal models
Before judging the efficiency of a procedure, thein which an infection such as peritonitis, instead of exo-
amount of a substance eliminated extracorporeally musttoxins or indotoxins, was employed to induce sepsis [33].
be established in relationship to the endogenous clear-A series of investigations has shown that hemofiltra-
ance (Table 2).tion does remove cytokines from the circulation by con-
Aside from the parameters listed in Table 1, the fol-vection [20, 21, 34–39]. Commonly, removal is expressed
lowing parameters are necessary for a calculation: molec-as a percentage of the blood or plasma concentration,
ular weight [41], sieving coefficient in vivo [10, 20, 21,and not as a portion of the total body amount or with
37–39, 42], virtual distribution volume in the body [43],respect to the metabolic clearance rate.
and internal elimination rate (half-life) [40, 43–50].
These reference data are listed in Table 3. Considering
CONDITIONS FOR SUCCESSFUL their molecular weights, a higher sieving coefficient could
MEDIATOR ELIMINATION be expected for most of the cytokines. However, binding
to circulating receptors or other proteins and secondaryEffective blood purification, and also in the case of
membrane formation in the hemofilters result in a de-mediators, generally takes place under three conditions:
crease in the sieving coefficient. That may be one reason(a) The extracorporeally eliminated amount must be of
why the coefficients vary considerably between investiga-consequence when regarding the total body amount. (b)
tors, between different membrane types, and are notWith respect to the endogenous clearance rate, the extra-
constant during the course of filtration. However, be-corporeal clearance rate must be so high that (c) the
cause of the short metabolic half-life, this variability is ofamount eliminated extracorporeally beneficially influ-
little significance when purifying the blood of cytokines.ences the course of the disease.
It is not clear whether or not the elimination of isolated The distribution volume of cytokines with a molecular
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Table 3. Molecular weight, sieving coefficients and endogenous half-lives of some cytokines
Molecular
Cytokines weight Sieving coefficient Half-life minutes
TNFa ,17.4 0–0.2,a 0.01–1.0 [52] ,6–7 [45] ,14–17 [43]
monomer ,15 [47]
trimer ,52
IL-1 ,18 0.07–0.42,b 0.35 [38] ,6–10 [44]
0.18 [39], 0.12–1.0 [52]
IL-2 ,6–10 [46]
IL-6 ,26 0.01–0.32 [52] ,6 [49]
IL-8 ,6–8 0.0–0.48,b 0.44 [39]
a Data are from the literature [10]
b Rising sieving coefficient during hemofiltration
Table 4. Mass removal by hemofiltration (%) in relation to the with different filtrate volumes and sieving coefficients is
endogenous half-life and dependence of filtrate volume and the
calculated. The calculation with higher sieving coeffi-sieving coefficient
cients demonstrates the mass transfer that can occur with
Half-life of mediator,
membrane improvement. Because no data are available100% endogenously removed
Filtrate Sieving about the half-life of mediators in patients with sepsisvolume coefficient 15 min 30 min 60 min 120 min
or SIRS, the calculations are carried out with half-lives
1 liter/hr 0.1 0.3 0.6 1.2 2.4
of up to 120 minutes.1 liter/hr 0.25 1 2 4 8
1 liter/hr 0.5 2 4 8 16
1 liter/hr 1 4 8 16 32
2 liter/hr 0.1 0.6 1.2 2.4 4.8 DISCUSSION2 liter/hr 0.25 2 4 8 16
2 liter/hr 0.5 4 8 16 32 The question of whether continual renal replacement
2 liter/hr 1.0 8 16 32 64
therapy (CRRT) has a beneficial effect on sepsis or SIRS
can be clarified only in controlled studies. Whether or
not substantial amounts of various mediators can be re-
moved by hemofiltration must be established by mea-weight below 20 kDa should correspond to at least the
extracorporeal space, which entails approximately 15% surement.
of the body weight. Determination of the half-life of the The results presented here with relevant data show
cytokines raises some problems. It is possible to estimate that hemofiltration can only remove insubstantial
the half-life after one dose of a labeled cytokine [49] or amounts of mediators, representing only a few percent-
by the slope of the curve after a single application of an ages, compared with endogenous clearance. In concur-
exotoxin or endotoxin. However, continuous formation rence, most investigators have reported no (abstract;
of cytokines must be considered [47]. No reference data Kierdorf et al, Ren Fail 14:98, 1992) [27, 42] or only
are available for the half-life of cytokines in patients minimal decreases in the plasma mediator concentration
with SIRS, where increased formation occurs. [51], even when employing hemofiltration over several
For the subsequent calculations, a half-life for TNF-a days. An effective mass removal is only possible with a
of 15 minutes has been employed, which corresponds to highly permeable membrane (sieving coefficient approx-
the half-life of other cytokines. An extracellular space imately 1.0), a high filtrate volume ($2 liter/hr), and
of 15 liters and a filtration volume of 1 liter/hr and a
when the half-life of the substance to be eliminated is
relatively high sieving coefficient for TNF-a of 0.25 are
greater than 60 minutes.assumed. With a plasma TNF-a concentration of 500
Membrane adsorption has not been taken into accountpg/ml or 500 ng/liter and an extracellular volume of 15
in these calculations. Adsorption onto the majority ofliters, a total amount of approximately 7500 ng TNF-a
membranes generally in use is low and only for poly-is calculated. During the 15-minute half-life, roughly
acrylonitrile membranes relatively high [52]. However,3750 ng are metabolized while at the same time, 250 ml
within a few hours, the adsorption on the membranefiltrate with approximately 30 ng TNF-a is removed.
surface is saturated. Frequent filter change or developingComparing the metabolized amount of TNF-a and the
special filters might generate more efficient adsorption,amount removed by hemofiltration, a mass transfer by
perhaps with better mass removal of mediators encoun-hemofiltration of only approximately 1% occurs. In-
tered during sepsis, but even during treatment with thiscreasing the sieving coefficient to 1 increases the amount
type of membrane, only a short transient drop of theremoved by hemofiltration to approximately 4%.
In Table 4, the mass removal of a single mediator TNF plasma level could be observed.
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W: Acute renal failure in abdominal infection: Comparison ofCONCLUSION
hemodialysis and continuous arteriovenous hemofiltration. Anasth
Following disappointing results of treating sepsis or Intensivther Notfallmed 21:212–217, 1986
13. Alarabi AA, Danielson BG, Wikstrom B, Wahlberg J: OutcomeSIRS with antibodies and receptor blockers for cyto-
of continuous arteriovenous hemofiltration (CAVH) in one centre.kines, hope had been invested in removing these sub- Ups J Med Sci 94:299–303, 1989
stances by blood purification. The calculations presented 14. Brian R, McDonald BR, Metha RL: Decreased mortality in
patients with acute renal failure undergoing continuous arteriove-here show that continuous hemofiltration can remove
nous hemodialysis. Contrib Nephrol 93:51–56, 1991only insubstantial amounts of mediators when compared 15. Bellomo R, Mansfield D, Rumble S, Shapiro J, Parkin G, Boyce
with endogenous clearance. This does not mean that N: Acute renal failure in critical illness: Conventional dialysis ver-
sus acute continuous hemodiafiltration. ASAIO J 38:654–657, 1992continuous renal replacement therapy (CRRT) cannot
16. Bellomo R, Boyce N: Continuous venovenous hemodiafiltrationpositively influence sepsis or SIRS in other ways. compared with conventional dialysis in critically ill patients with
acute renal failure. ASAIO J 30:794–797, 1993Reprint requests to Dr. Heinz-Gu¨nter Sieberth, Medical Klinik II, 17. Kruczynski K, Irvine-Bird K, Toffelmire EB, Morton AR: AUniversita¨tsklinikum, Pauwelsstrasse 30, D52074 Aachen, Germany. comparison of continuous arteriovenous hemofiltration and inter-
mittent hemodialysis in acute renal failure patients in the intensive
care unit. ASAIO J 39:778–781, 1993REFERENCES
18. Coraim F, Fasol R, Stellwag F, Wolner TL: Continuous arterio-
1. Calandra T: Immunomodulation for Sepsis and Septic Shock. venous hemofiltration (CAVH) after cardiac surgery: Continuous
Abstracts 25. Ludwig-Heilmeyer-Symposium. Neue Erkenntnisse Arteriovenous Hemofiltration (CAVH). International Conference
in der Infektiologie; Ko¨ln 05.11.-07.11., 1998 on CAVH, Aachen, Basel, Karger, 1985, pp 116–124
2. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, 19. Gotloib L, Barzilay E, Shustak A, Wais Z, Jaichenko J, Lev
Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman A: Hemofiltration in septic ARDS: The artificial kidney as an
RL: Recombinant human interleukin 1 receptor antagonist in the artificial endocrine lung. Resuscitation 13:123–132, 1986
treatment of patients with sepsis syndrome: Results from a random- 20. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemo-
ized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sep- filtration with dialysis removes cytokines from the circulation of
sis Syndrome Study Group. JAMA 271:1836–1843, 1994 septic patients. Crit Care Med 4:522–526, 1993
3. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: 21. Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R,
Treatment of septic shock with human monoclonal antibody HA- Schultheis HP, Stauer BE, Grabensee B: Cytokine removal and
1A.A randomized, double-blind, placebo-controlled trial: CHESS cardiovascular hemodynamics in septic patients with continuous
Trial Study Group. Ann Intern Med 121:1–5, 1994 hemofiltration. Intensive Care Med 23:288–296, 1997
4. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway 22. Sander A, Armbruster W, Sander B, Thurauf N, Lange R,S, Levy H, Bone R, Wenzel RP, Balk R, Allred R: Efficacy Peters J: Hemofiltration increases IL-6 clearance in early systemicand safety of monoclonal antibody to human tumor necrosis factor
inflammatory response syndrome but does not alter IL-6 and TNFaalpha in patients with sepsis syndrome: A randomized, controlled,
plasma concentrations. Intensive Care Med 23:878–884, 1997double-blind, multicenter clinical trial. RNF-Alpha Mab Sepsis
23. Braun N, Rosenfeld S, Giolai M, Banzhaf W, Fretscher R,Study Group. JAMA 273:934–941, 1995
Warth H, Weinstock C, Deppisch R, Erley CM, Muller GA,5. Cohen J, Carlet J: Intersept: An international, multicenter, pla-
Risler T: Effect of continuous hemodiafiltration on IL-6, TNF-a,cebo-controlled trial of monoclonal antibody to human tumor ne-
C3a, and TCC in patients with SIRS/septic shock using two differ-crosis factor-alpha in patients with sepsis. International Sepsis Trial
ent membranes. Contrib Nephrol 116:89–98, 1995Study Group. Crit Care Med 24:1431–1440, 1996
24. Riegel W, Ziegenfuss T, Rose S, Bauer M, Marzi I: Influence6. Knaus WA, Harrell FE Jr, LaBrecque JF, Wagner DP, Pribble
of venovenous hemofiltration on posttraumatic inflammation andJP, Draper EA, Fisher CJ Jr, Soll L: Use of predicted risk of
hemodynamics. Contrib Nephrol 116:56–61, 1995mortality to evaluate the efficacy of anticytokine therapy in sepsis.
25. Cosentino F, Paganini E, Lockrem J, Stoler J, Wiedemann H:The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care
Continuous arteriovenous hemofiltration in the adult respiratoryMed 1:46–56, 1996
distress syndrome. Contrib Nephrol 93:94–97, 19917. Opal SM, Fischer CJ Jr, Dhainaut JF, Vincent JL, Brase R,
26. Bellomo R, Baldwin I, Cole L, Ronco C: Preliminary experienceLowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly
with high-volume hemofiltration in human septic shock. KidneyMP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H,
Int 53(Suppl 66):182–185, 1998Dubin H, Baughman R, Norman J, Demaria E, Matzel K, Abra-
27. Wakabayashi Y, Kamijou Y, Soma K, Ohwada T: Removal ofham E, Seneff M: Confirmatory interleukin-1 receptor antagonist
circulating cytokines by continuous hemofiltration in patients withtrial in severe sepsis: A phase III, randomized, double-blind, pla-
systemic inflammatory response syndrome of multiple organ dys-cebo-controlled, multicenter trial. The Interleukin-1 Receptor An-
function syndrome. Br J Surg 83:393–394, 1996tagonist Sepsis Investigator Group. Crit Care Med 7:1115–1124,
28. Staubach KH, Rau HG, Kooistra A, Shardey HM, Hohlbach1997
G, Schildberg FW: Can hemofiltration increase survival in acute8. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro
endotoxemia: A porcine shock model. Prog Clin Biol Res 308:821–G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Goo-
826, 1989ney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L,
29. Stein B, Pfenninger E, Grunert A, Schmitz JE, Hudde M: Influ-Allred R, Constant J, Pennington J, Porter S: Double-blind
ence of continuous haemofiltration on haemodynamics and centralrandomised controlled trial of monoclonal antibody to human tu-
blood, in experimental endotoxic shock. Intensive Care Medmour necrosis factor in treatment of septic shock. NORASEPT
16:494–499, 1990II Study Group. Lancet 351:929–933, 1998
30. Heidemann SM, Ofenstein JP, Sarnaik AP: Efficacy of continu-9. Fisher CHJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff
ous arteriovenous hemofiltration in endotoxic shock. Circ ShockJG, Abraham E, Schein RMH, Benjamin E: Treatment of septic
44:183–187, 1994shock with the tumor necrosis factor receptor: Fc fusion protein.
31. Lee PA, Weger GW, Pryror RW, Matson JR: Effects of filterN Engl J Med 334:1697–1702, 1996
pore size on efficacy of continuous arteriovenous hemofiltration10. Schetz M: Non-renal indications for CRRT. Kidney Int 56(Suppl
therapy for Staphylococcus aureus-induced septicemia in immature72):this issue, 1999
swine. Crit Care Med 26:730–737, 199811. Kierdorf H, Sieberth HG: Continuous treatment modalities in
32. Lee PA, Matson JR, Pryor RW, Hinshaw LB: Continuous arte-acute renal failure. Nephrol Dial Transplant 10:2001–2008, 1995
12. Mauritz W, Sporn P, Schindler I, Zadrobilek E, Roth E, Appel riovenous hemofiltration therapy for Staphylococcus aureus-
Sieberth and Kierdorf: Cytokine removal by continuous hemofiltration S-83
induced septicemia in immature swine? Crit Care Med 21:914–924, during continuous hemofiltration: A laboratory and clinical study.
Contrib Nephrol 116:62–75, 19951993
33. Freeman BD, Yatsiv I, Natanson C, Solomon MA, Quezado 43. Blick M, Sherwin SA, Rosenblum M, Gutterman J: Phase I
study of recombinant tumor necrosis factor in cancer patients.ZMN, Danner RL, Banks SM, Hoffman W: Continuous arterio-
venous hemofiltration does not improve survival in a canine model Cancer Res 47:2986–2989, 1987
44. Lotze MT, Robb RJ, Sharrow SA: Systemic administration ofof septic shock. J Am Coll Surg 180:286–292, 1995
34. Bellomo R, Tipping P, Boyce N: Tumor necrosis factor clearances interleukin-2 in humans. J Biol Response Mod 3:475–482, 1984
45. Beutler BA, Milsark IW, Cerami A: Cachectin/tumor necrosisduring veno-venous hemofiltration in the critically ill. Trans Am
Soc Artif Intern Organs 37:322–332, 1991 factor: Production, distribution, and metabolic fate in vivo. J Immu-
nol 135:3972–3977, 198535. Barrera P, Janssen EM, Demacker PNM, Wetzels JFM, Van
der Meer JWM: Removal of interleukin-1beta and tumor necrosis 46. Newton RC, Uhl J, Covington M, Back O: The distribution
and clearance of radiolabeled human interleukin-1 beta in mice.factor from human plasma by in vitro dialysis with polyacrylonitrile
membranes. Lymphokine Cytokine Res 11:99–104, 1992 Lymphokine Res 7:207–216, 1988
47. Lowry SF, Van Zee KJ, Rock CS, Thompson WA, Oldenburg36. Lonnemann G, Schindler R, Dinarello CA, Koch KM: Removal
of circulating cytokines by hemodialysis membranes in vitro, in HSA, Rogy MA, Moldawer LL: Tumor necrosis factor as a media-
tor of sepsis, in Shock, Sepsis and Organ Failure, edited by SchlagHost Defense Dysfunction in Shock and Sepsis, edited by Faist E,
Meakins J, Schildberg FW, Berlin-Heidelberg, Springer Verlag, GA, Redl H, Berlin, Heidelberg, Springer, 1993, pp 13–14
48. Moldawer LL, Fischer E, Van Lee KJ, Thompson WA, Lowry1992, pp 613–623
37. Goldfarb S, Golper TA: Proinflammatory cytokines and hemofil- SF: A role for interleukin-1 in septic shock, in Shock, Sepsis and
Organ Failure, edited by Schlag GA, Redl H, Berlin, Heidelberg,tration membranes. J Am Soc Nephrol 5:228–232, 1994
38. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, In- Springer, 1993, pp 18–25
49. Castell J, Klapproth J, Gross V, Eike WE, Andus T, Snyersthorn D: Hemofiltration in human sepsis: Evidence for elimination
of immunomodulatory substances. Kidney Int 48:1563–1570, 1995 L, Content J, Heinrich PC: Fate of interleukin-6 in the rat. Eur
J Biochem 189:113–118, 199039. Van Bommel EFH, Hesse CJ, Jutte NHPM, Zietse R, Bruining
HA, Weimar W: Impact of continuous hemofiltration on cytokines 50. Borth W, Luger TA: Identification of a2-macroglobulin as a cyto-
kine binding plasma protein. J Biol Chem 264:5818–5825, 1989and cytokine inhibitors in oliguric patients suffering from systemic
inflammatory response syndrome. Ren Fail 19:443–454, 1997 51. Kellum JA, Johnson JP, Kramer S, Palevsky P, Brady JJ, Pinsky
MR: Diffusive versus convective therapy: Effects on mediators of40. Fong J, Moldawer LL, Shires GT, Lowry SF: The biological
characteristics of cytokines and their implication in surgical injury. inflammation in patient with severe systemic inflammatory re-
sponse syndrome. Crit Care Med 26:1995–2000, 1998Surg Gynecol Obstet 170:365–378, 1990
41. Callard R, Gearing A: The Cytokine Facts Book. London, San 52. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De
Sutter JH, Lameire NH: Cytokine removal during continuousDiego, Academic Press Harcourt Brace & Company, 1994
42. Van Bommel EFH, Hesse CJ, Jutte NHPM, Zietse R, Bruining hemofiltration in septic patients. J Am Soc Nephrol 10:846–853,
1999HA, Weimar W: Cytokine kinetics (TNF-alpha, IL-1beta, IL-6)
